Psychedelics Don’t Just “Turn Up” the Brain: What 49 Electrophysiology Studies Actually Show

For years, a tidy story has circulated about how classic psychedelics work: they hit the brain’s 5-HT2A receptors, crank up activity in the cortex, and the flood of excitation produces the altered state. A new systematic review in Neuroscience & Biobehavioral Reviews suggests that “volume knob” picture is too simple — and that the truth looks more like a conductor reorganizing an orchestra than someone turning everything up at once.

What the review looked at

The authors gathered and critically evaluated 49 electrophysiology studies — 23 in cells/tissue (in vitro) and 26 in living animals (in vivo) — that recorded the electrical behavior of neurons under psychedelics. That is a different lens than the brain-imaging studies most coverage relies on: instead of blood-flow maps, electrophysiology listens to how individual neurons and local circuits actually fire.

Much of the attention lands on layer 5 pyramidal neurons in the prefrontal cortex. These are big, deeply interconnected cells whose apical dendrites are dense with 5-HT2A receptors — the main docking site for classic psychedelics — and they sit at a hub of cortical computation and thalamic communication, which is part of why researchers regard them as central to how the cortex works.

The headline finding: not “more,” but “reorganized”

Across the studies, the effects were heterogeneous — not a uniform increase in excitability. The review reports that psychedelics appear to modulate both excitatory and inhibitory processes, in ways that depend on:

• The cell type and even the compartment of the neuron (the dendrites can behave differently than the cell body).
• The dose — with biphasic responses, where low and high doses can push in different directions.
• The context — the surrounding circuit state and conditions shaped what happened.

In other words, the same drug did not simply make every neuron fire more. Layer 5 pyramidal cells — long assumed to just ramp up under psychedelics — often behaved in more nuanced ways once researchers measured them directly. The pattern that emerges may suggest a reorganization of activity across excitatory and inhibitory circuits, rather than a blanket boost.

Why this matters

If the “reorganization” picture holds up, it reframes some common assumptions:

• Mechanism talk gets more careful. “Psychedelics increase brain excitability” is a headline; the electrophysiology was associated with a messier, more balanced set of effects that any real mechanism story has to account for.
• It connects to the imaging debate. Neuroimaging can show where things change but not the fine-grained how. Pairing it with electrophysiology gives researchers a fuller — and more complicated — view.
• It sets up better questions. Dose-dependence and cell-specificity are exactly the kinds of details that matter if scientists want to understand these compounds rather than just describe them.

What it does not establish

A few honest caveats:

• This is a review of mechanism studies, mostly in cells and animals. It describes how neurons behave, not what psychedelics do for any health condition in people — and it is not medical, dosing, or treatment advice.
• “Reorganization” is an interpretation of converging data, not a single confirmed switch. Electrophysiology studies vary in method and quality, and the authors themselves emphasize how heterogeneous the results are.
• Animal and in vitro findings do not automatically transfer to the human brain. They are a foundation for more research, not a conclusion about human experience.

The useful takeaway is smaller and more interesting than the usual headline: when you actually record the neurons, psychedelics look less like a volume knob and more like a rearrangement — and that nuance is where the real science is heading.

ShroomWire reports on mushroom, psychedelic, and brain-health research. We are not doctors, and nothing here is medical, dosing, or treatment advice.

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.